Circulating Galectin-3 Levels Are Increased in Patients with Ischemic Heart Disease, but Are Not Influenced by Acute Myocardial Infarction

Cardiology (Switzerland)

Volumn 134, Issue 4, 2016, Pages 398-405

  Singsaas, Erlend G ^a   Manhenke, Cord A ^a   Dickstein, Kenneth ^a,b   Orn, Stein ^a,b  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Biomarkers; Cardiac magnetic resonance imaging; Galectin 3; Left ventricular remodeling; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIURETIC AGENT; GADODIAMIDE; GALECTIN 3; TROPONIN T;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE VOLUME; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SINGLE VESSEL DISEASE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; VASCULAR DISEASE; ANGIOGRAPHY; BLOOD; CINE MAGNETIC RESONANCE IMAGING; CORONARY BLOOD VESSEL; DIAGNOSTIC IMAGING; HEART MUSCLE ISCHEMIA; HEART STROKE VOLUME; HEART VENTRICLE; HEART VENTRICLE REMODELING; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX; STATISTICS;

AGED; ANGIOGRAPHY; C-REACTIVE PROTEIN; CORONARY VESSELS; FEMALE; GALECTIN 3; HEART VENTRICLES; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PERCUTANEOUS CORONARY INTERVENTION; SEVERITY OF ILLNESS INDEX; ST ELEVATION MYOCARDIAL INFARCTION; STATISTICS AS TOPIC; STROKE VOLUME; VENTRICULAR REMODELING;

EID: 84966560504     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000445103     Document Type: Article

References (35)

1. Mendis S, Puska P, Norrving B: Global atlas on cardiovascular disease prevention and control. World Health Organization, Geneva, 2011.
2. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ: Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009; 11: 811-817.
3. Filipe MD, Meijers WC, Rogier van der Velde A, de Boer RA: Galectin-3 and heart failure: prognosis, prediction and clinical utility. Clin Chim Acta 2015; 443: 48-56.
4. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, Larson MG, Levy D: Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 2012; 60: 1249-1256.
5. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, Bakker SJ, van der Harst P: The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012; 272: 55-64.
6. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL: Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010; 12: 826-832.
7. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ: Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011; 43: 60-68.
8. de Boer RA, Edelmann F, Cohen-Solal A, Mamas MA, Maisel A, Pieske B: Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail 2013; 15: 1095-1101.
9. Carrasco-Sanchez FJ, Aramburu-Bodas O, Salamanca-Bautista P, Morales-Rull JL, Galisteo-Almeda L, Paez-Rubio MI, Arias-Jimenez JL, Aguayo-Canela M, Perez-Calvo JI: Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction. Int J Cardiol 2013; 169: 177-182.
10. Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, Adourian A, Bohm M, van Veldhuisen DJ, Komajda M, Cleland JG, Wikstrand J, McMurray JJ, Aukrust P, Group CS: Galectin-3 predicts response to statin therapy in the controlled rosuvastatin multinational trial in heart failure (corona). Eur Heart J 2012; 33: 2290-2296.
11. Anand IS, Rector TS, Kuskowski M, Adourian A, Muntendam P, Cohn JN: Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail 2013; 15: 511-518.
12. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson Writing Committee Members, Yancy CW, Jessup M, Bozkurt B, et al: 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on practice guidelines. Circulation 2013; 128: 240-327.
13. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; ESC Committee for Practice Guidelines: Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847.
14. Maiolino G, Rossitto G, Pedon L, Cesari M, Frigo AC, Azzolini M, Plebani M, Rossi GP: Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2015; 35: 725-732.
15. Manhenke C, Orn S, von Haehling S, Wollert KC, Ueland T, Aukrust P, Voors AA, Squire I, Zannad F, Anker SD, Dickstein K: Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction. Int J Cardiol 2013; 166: 729-735.
16. Sutton MG, Sharpe N: Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000; 101: 2981-2988.
17. Meijers WC, van der Velde AR, Pascual-Figal DA, de Boer RA: Galectin-3 and post-myocardial infarction cardiac remodeling. Eur J Pharmacol 2015; 763: 115-121.
18. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752-760.
19. Liu YH, D'Ambrosio M, Liao TD, Peng H, Rhaleb NE, Sharma U, Andre S, Gabius HJ, Carretero OA: N-acetyl-seryl-aspartyl-lysylproline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 2009; 296:H404-H412.
20. Tsai TH, Sung PH, Chang LT, Sun CK, Yeh KH, Chung SY, Chua S, Chen YL, Wu CJ, Chang HW, Ko SF, Yip HK: Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. J Atheroscler Thromb 2012; 19: 1073-1082.
21. Mayr A, Klug G, Mair J, Streil K, Harrasser B, Feistritzer HJ, Jaschke W, Schocke M, Pachinger O, Metzler B: Galectin-3: relation to infarct scar and left ventricular function after myocardial infarction. Int J Cardiol 2013; 163: 335-337.
22. Weir RA, Petrie CJ, Murphy CA, Clements S, Steedman T, Miller AM, McInnes IB, Squire IB, Ng LL, Dargie HJ, McMurray JJ: Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail 2013; 6: 492-498.
23. van der Velde AR, Lexis CP, Meijers WC, van der Horst IC, Lipsic E, Dokter MM, van Veldhuisen DJ, van der Harst P, de Boer RA: Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. Clin Chim Acta 2016; 452: 50-57.
24. Lexis CP, van der Horst IC, Lipsic E, Wieringa WG, de Boer RA, van den Heuvel AF, van der Werf HW, Schurer RA, Pundziute G, Tan ES, Nieuwland W, Willemsen HM, Dorhout B, Molmans BH, van der Horst-Schrivers AN, Wolffenbuttel BH, ter Horst GJ, van Rossum AC, Tijssen JG, Hillege HL, de Smet BJ, van der Harst P, van Veldhuisen DJ; GIPS-III Investigators: Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. JAMA 2014; 311: 1526-1535.
25. Alturfan AA, Basar I, Emekli-Alturfan E, Ayan F, Koldas L, Emekli N: Galectin-3 and plasma cytokines in patients with acute myocardial infarction. Lab Med 2014; 45: 336-341.
26. Kruk M, Menon V, Kadziela J, Sadowski Z, Ruzyllo W, Janas J, Roik M, Opolski G, Zmudka K, Czunko P, Kurowski M, Busz-Papiez B, Zinka E, Jablonski W, Jaworska K, Raczynska A, Skonieczny G, Forman S, Li D, Hochman J: Impact of percutaneous coronary intervention on biomarker levels in patients in the subacute phase following myocardial infarction: the Occluded Artery Trial (OAT) biomarker ancillary study. BMC Cardiovasc Disord 2013; 13: 91.
27. Sanchez-Mas J, Lax A, Asensio-Lopez MC, Fernandez-Del Palacio MJ, Caballero L, Garrido IP, Pastor F, Januzzi JL, Pascual-Figal DA: Galectin-3 expression in cardiac remodeling after myocardial infarction. Int J Cardiol 2014; 172:e98-e101.
28. Lopez B, Gonzalez A, Querejeta R, Zubillaga E, Larman M, Diez J: Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. Eur J Heart Fail 2015; 17: 385-392.
29. Orn S, Manhenke C, Anand IS, Squire I, Nagel E, Edvardsen T, Dickstein K: Effect of left ventricular scar size, location, and transmurality on left ventricular remodeling with healed myocardial infarction. Am J Cardiol 2007; 99: 1109-1114.
30. Wu E, Ortiz JT, Tejedor P, Lee DC, Bucciarelli-Ducci C, Kansal P, Carr JC, Holly TA, Lloyd-Jones D, Klocke FJ, Bonow RO: Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or endsystolic volume index: prospective cohort study. Heart 2008; 94: 730-736.
31. Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM, Antoniucci D: Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation 2002; 106: 2351-2357.
32. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ: Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76: 44-51.
33. Orn S, Manhenke C, Squire IB, Ng L, Anand I, Dickstein K: Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function. J Card Fail 2007; 13: 843-849.
34. Manhenke C, Ueland T, Jugdutt BI, Godang K, Aukrust P, Dickstein K, Orn S: The relationship between markers of extracellular cardiac matrix turnover: infarct healing and left ventricular remodelling following primary PCI in patients with first-time STEMI. Eur Heart J 2014; 35: 395-402.
35. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.